检索历史清除

首页> Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research> Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles (vol 77, pg 1837, 2017)

Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles (vol 77, pg 1837, 2017)

导出原文传递

翻译打印收藏纠错

作者： Chamberlain, C. ; Colman, P. J. ; Ranger, A. M. ; Burkly, L. C. ; Johnston, G., I ; Otoul, C. ; Stach, C. ; Zamacona, M. ; Dorner, T. ; Urowitz, M. ; Hiepe, F.

发布时间 2018-12-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交